Lycia Therapeutics

Our President & CEO, Aetna Wun Trombley will participate in a panel next Wed., June 5th at #BIO2024 in San Diego, moderated by Mariana Mihalusova at Venrock, focused on novel approaches to co-opting biological processes with various modalities to drug a spectrum of diseases.    Other panelists include George Eliades at Mythic Therapeutics, Inc.; Larry Hamann at Interdict Bio; and Bernd Boidol at Proxygen.   At Lycia, we're hijacking the naturally occurring lysosomal trafficking process to degrade disease-driving extracellular proteins. We've built a robust internal pipeline of LYTAC degraders and are advancing our lead programs in #autoimmune and #inflammatory diseases toward the clinic.   #BIO24 #proteindegradation

A big thanks to @NYSE for celebrating our Series C financing on the trading floor last week! We're excited to continue advancing our lead LYTAC degraders toward the clinic for #autoimmune and #inflammatory diseases! #NYSE

A big thanks to @NYSE for celebrating our Series C financing on the trading floor last week! We're excited to continue advancing our lead LYTAC degraders toward the clinic for #autoimmune and #inflammatory diseases! #NYSE

We're excited to welcome Andrew Gottesdiener, M.D., Partner at Venrock, to our Board of Directors, concurrent with our $106.6M Series C financing, announced yesterday. We look forward to continuing to advance our lead LYTAC extracellular protein degraders toward the clinic for #autoimmune and #inflammatory diseases! Read yesterday's press release: https://bit.ly/44EG63u

Thanks to Endpoints News and Kyle LaHucik for the great article on our Series C financing and catching up with our President & CEO Aetna Wun Trombley on our continued progress toward the clinic with our lead LYTAC extracellular protein degrader programs for autoimmune and inflammatory diseases. https://lnkd.in/eTgcNucb

We're thrilled to announce the completion of a $106.6 million Series C financing to progress our lead LYTAC extracellular protein degraders into the clinic for unmet needs in #autoimmune and #inflammatory diseases. Venrock Healthcare Capital Partners led the round, with participation from new investors Janus Henderson Investors, Marshall Wace and Franklin Templeton, and existing investors Redmile Group, RTW Investments, LP, Blue Owl Capital (Blue Owl Healthcare Opportunities), Invus, Eli Lilly and Company and Alexandria Venture Investments. Read the release: https://bit.ly/44EG63u

We’re #hiring a new Principal/Senior Scientist, Pharmacokinetics (PK) in San Francisco, California. Apply today or share this post with your network.

We’re #hiring a new Scientist I/II Molecular Biology & Protein Expression in San Francisco, California. Apply today or share this post with your network.

We’re #hiring a new Principal/Senior Scientist, Pharmacokinetics (PK) in South San Francisco, California. Apply today or share this post with your network.

Lycia Therapeutics is hiring! Join a company that is passionate about science and dedicated to the company’s vision and mission of delivering transformational medicines that eliminate drivers of human disease by targeting the extracellular proteome.  Open Positions: Senior/Research Associate, Biology Principal/Senior Scientist, Pharmacokinetics/Modeling & Simulation https://lnkd.in/gGVzS6Tb #hiring #biotech #scientist #researchassociate #biology #ssf